AZD-8186 Recruiting Phase 1 Trials for Advanced Breast Carcinoma / Stage IVB Prostate Cancer AJCC v8 / Prognostic Stage IIIB Breast Cancer AJCC v8 / Prognostic Stage IIIC Breast Cancer AJCC v8 / Stage IVA Prostate Cancer AJCC v8 / Metastatic Malignant Solid Neoplasm / Prognostic Stage III Breast Cancer AJCC v8 / Anatomic Stage IIIA Breast Cancer AJCC v8 / Unresectable Solid Neoplasm / Stage IIIC Prostate Cancer AJCC v8 / Triple-Negative Breast Carcinoma / Stage IIIA Prostate Cancer AJCC v8 / Anatomic Stage III Breast Cancer AJCC v8 / Advanced Prostate Carcinoma / Advanced Malignant Solid Neoplasm / Castration-Resistant Prostate Carcinoma / Prognostic Stage IV Breast Cancer AJCC v8 / Anatomic Stage IIIB Breast Cancer AJCC v8 / Metastatic Hormone Refractory Prostate Cancer / Stage III Prostate Cancer AJCC v8 / Stage IIIB Prostate Cancer AJCC v8 / Anatomic Stage IV Breast Cancer AJCC v8 / Prognostic Stage IIIA Breast Cancer AJCC v8 / Stage IV Prostate Cancer AJCC v8 / Anatomic Stage IIIC Breast Cancer AJCC v8 / Metastatic Breast Carcinoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03218826PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery